RETA Reata Pharmaceuticals, Inc.

20.60
0  -1%
Previous Close 20.80
Open 20.82
Price To book 0.00
Market Cap 460.29M
Shares 22,344,000
Volume 53,868
Short Ratio 26.79
Av. Daily Volume 48,740

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 trial initiation announced February 23, 2017. Data from Phase 2 part of trial due by the end of 2017.
Bardoxolone methyl - CARDINAL
Chronic Kidney Disease Caused by Alport Syndrome
Phase 2 enrollment commenced January 2017.
Bardoxolone methyl - LARIAT
Pulmonary hypertension due to interstitial lung disease - PH-ILD
Phase 3 commenced enrolment October 2016 with data due 1H 2018.
Bardoxolone methyl - CATALYST
Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH
Phase 2 initial data due mid-2017.
Omaveloxolone - MOXIe
Friedreich’s ataxia (FA)
Phase 2 initial data due 2H 2017.
Omaveloxolone - MOTOR
Mitochondrial myopathies (MM)
Phase 1b portion of trial due 2H 2017.
Omaveloxolone - REVEAL
Metastatic melanoma